https://www.selleckchem.com/products/Y-27632.html
MenABCWY vaccination was immunogenic against MenB test strains. Non-inferiority for all 4 components of the 4CMenB vaccine could not be demonstrated for the 0-2 M schedule. Antibodies persisted up to 2 years post-MenABCWY vaccination and a booster dose induced an anamnestic response as higher titers were observed in follow-on participants compared to the first-dose response in vaccine-naïve participants. link2 MenABCWY had a clinically-acceptable safety profile, not different from that of 4CMenB.Considered to be a field that is continuo
Curtir
Comentario
Compartilhar
